Becker Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

Becker Muscular Dystrophy Pipeline Drugs Market Report Overview

Becker muscular dystrophy pipeline market research report provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Becker Muscular Dystrophy and features dormant and discontinued projects.

Key Targets in the Becker Muscular Dystrophy Pipeline Market

The key targets in the Becker Muscular Dystrophy pipeline market are Androgen Receptor, Cardiolipin, Follistatin, Glucagon Like Peptide 1 Receptor, Glucocorticoid Receptor, Growth/Differentiation Factor 8, Histone Deacetylase 1, Histone Deacetylase 2, Myosin ATPase, and Ryanodine Receptor.

Key MoA in the Becker Muscular Dystrophy Pipeline Market

The key MoA in the Becker Muscular Dystrophy pipeline market are Androgen Receptor Agonist, Follistatin Activator, Glucagon Like Peptide 1 Receptor Agonist, Glucocorticoid Receptor Agonist, Growth/Differentiation Factor 8 Inhibitor, Histone Deacetylase 1 Inhibitor, and Histone Deacetylase 2 Inhibitor.

Key RoA in the Becker Muscular Dystrophy Pipeline Market

The key RoA in the Becker Muscular Dystrophy pipeline market are oral, intravenous, subcutaneous, intramuscular, and ophthalmic. Oral has the highest number of pipeline products.

Becker Muscular Dystrophy Pipeline Market, by RoA

Becker Muscular Dystrophy Pipeline Market, by RoA

For more RoA insights, download a free report sample

Key Molecule Types in the Becker Muscular Dystrophy Pipeline Market

The key molecule types in the Becker Muscular Dystrophy pipeline market are small molecule, fusion protein, gene therapy, monoclonal antibody, recombinant protein, and synthetic peptide. Small molecule has the highest number of pipeline products.

Becker Muscular Dystrophy Pipeline Market, by Molecule Types

Becker Muscular Dystrophy Pipeline Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Companies in the Becker Muscular Dystrophy Pipeline Market

The key companies in the Becker Muscular Dystrophy pipeline market are Epirium Bio Inc, ARMGO Pharma Inc, Edgewise Therapeutics Inc, Italfarmaco SpA, Milo Biotechnology LLC, PhaseBio Pharmaceuticals Inc, Santhera Pharmaceuticals Holding AG, and Sarcomed AB. Epirium Bio Inc has the highest number of pipeline products.

Becker Muscular Dystrophy Pipeline Market, by Companies

Becker Muscular Dystrophy Pipeline Market, by Companies

To know more about companies, download a free report sample

Market report overview

Key targets Androgen Receptor, Cardiolipin, Follistatin, Glucagon Like Peptide 1 Receptor, Glucocorticoid Receptor, Growth/Differentiation Factor 8, Histone Deacetylase 1, Histone Deacetylase 2, Myosin ATPase, and Ryanodine Receptor
Key MoA Androgen Receptor Agonist, Follistatin Activator, Glucagon Like Peptide 1 Receptor Agonist, Glucocorticoid Receptor Agonist, Growth/Differentiation Factor 8 Inhibitor, Histone Deacetylase 1 Inhibitor, and Histone Deacetylase 2 Inhibitor
Key RoA Oral, Intravenous, Subcutaneous, Intramuscular, and Ophthalmic
Key molecule types Small Molecule, Fusion Protein, Gene Therapy, Monoclonal Antibody, Recombinant Protein, and Synthetic Peptide
Key companies Epirium Bio Inc, ARMGO Pharma Inc, Edgewise Therapeutics Inc, Italfarmaco SpA, Milo Biotechnology LLC, PhaseBio Pharmaceuticals Inc, Santhera Pharmaceuticals Holding AG, and Sarcomed AB

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Becker Muscular Dystrophy (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Becker Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Becker Muscular Dystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Becker Muscular Dystrophy (Genetic Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Becker Muscular Dystrophy (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Becker Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

ARMGO Pharma Inc
Edgewise Therapeutics Inc
Epirium Bio Inc
Italfarmaco SpA
Milo Biotechnology LLC
PhaseBio Pharmaceuticals Inc
Santhera Pharmaceuticals Holding AG
Sarcomed AB
Scholar Rock Inc
Stealth BioTherapeutics Corp
Tivorsan Pharmaceuticals Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Becker Muscular Dystrophy – Overview

Becker Muscular Dystrophy – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Becker Muscular Dystrophy – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Becker Muscular Dystrophy – Companies Involved in Therapeutics Development

ARMGO Pharma Inc

Edgewise Therapeutics Inc

Epirium Bio Inc

Italfarmaco SpA

Milo Biotechnology LLC

PhaseBio Pharmaceuticals Inc

Santhera Pharmaceuticals Holding AG

Sarcomed AB

Scholar Rock Inc

Stealth BioTherapeutics Corp

Tivorsan Pharmaceuticals Inc

Becker Muscular Dystrophy – Drug Profiles

apitegromab – Drug Profile

Product Description

Mechanism Of Action

History of Events

ARM-210 – Drug Profile

Product Description

Mechanism Of Action

History of Events

dextro epicatechin – Drug Profile

Product Description

Mechanism Of Action

History of Events

EDG-5506 – Drug Profile

Product Description

Mechanism Of Action

History of Events

elamipretide hydrochloride – Drug Profile

Product Description

Mechanism Of Action

History of Events

epicatechin – Drug Profile

Product Description

Mechanism Of Action

History of Events

Gene therapy To Activate Follistatin For Duchenne Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, Becker Muscular Dystrophy And Inclusion Body Myositis – Drug Profile

Product Description

Mechanism Of Action

History of Events

givinostat – Drug Profile

Product Description

Mechanism Of Action

History of Events

nandrolone decanoate – Drug Profile

Product Description

Mechanism Of Action

PB-1023 – Drug Profile

Product Description

Mechanism Of Action

History of Events

TVN-102 – Drug Profile

Product Description

Mechanism Of Action

History of Events

vamorolone – Drug Profile

Product Description

Mechanism Of Action

History of Events

Becker Muscular Dystrophy – Dormant Projects

Becker Muscular Dystrophy – Discontinued Products

Becker Muscular Dystrophy – Product Development Milestones

Featured News & Press Releases

Apr 14, 2022: Edgewise-Funded natural history trial of Becker Muscular Dystrophy (BMD) now enrolling

Mar 08, 2022: Edgewise Therapeutics to present on EDG-5506 for Becker and Duchenne Muscular Dystrophy (BMD, DMD) at the 2022 Annual MDA Clinical and Scientific Conference

Jan 05, 2022: Edgewise Therapeutics announces positive topline results from the EDG-5506 phase 1b clinical trial in adults with Becker Muscular Dystrophy (BMD)

Dec 15, 2021: Edgewise Therapeutics to report phase 1b topline results of EDG-5506 in individuals with Becker muscular dystrophy (BMD) on January 5, 2022, and initiates ARCH follow-on open label BMD study

Oct 28, 2021: Edgewise Therapeutics announces positive topline results from the EDG-5506 phase 1 multiple ascending dose (MAD) study in healthy volunteers (HVs) and doses first Becker Muscular Dystrophy (BMD) patients

Sep 27, 2021: ReveraGen and Santhera announce FDA orphan grant funding for clinical trial with vamorolone in Becker muscular dystrophy

Aug 16, 2021: Edgewise receives U.S. FDA Fast Track Designation for EDG-5506 for the treatment of individuals with Becker muscular dystrophy (BMD)

Jun 26, 2021: Italfarmaco announces topline data from phase 2 trial with Givinostat in patients with Becker Muscular Dystrophy

May 04, 2021: Edgewise Therapeutics announces publication of data demonstrating the elevation of fast but not slow skeletal muscle fiber injury biomarkers in the circulation of patients with Becker and Duchenne Muscular Dystrophy

Feb 22, 2021: Italfarmaco provides update on ongoing clinical programs with givinostat in oral presentation at XVIII International Conference on Duchenne and Becker Muscular Dystrophy

Nov 11, 2020: Edgewise Therapeutics initiates phase 1 clinical trial of EDG-5506 in Becker muscular dystrophy

Oct 29, 2020: Edgewise Therapeutics appoints John Moore as general counsel

Aug 12, 2020: Epirium Bio announces commencement of phase 1 clinical trial of EPM-01 in Becker muscular dystrophy

Apr 14, 2020: Epirium Bio receives FDA orphan-drug designation for EB 002 ((+)-Epicatechin) for the treatment of duchenne and becker muscular dystrophy

Jun 30, 2015: Cardero Therapeutics Presents at 2015 Parent Project Muscular Dystrophy Connect Conference

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Becker Muscular Dystrophy, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Becker Muscular Dystrophy – Pipeline by ARMGO Pharma Inc, 2022

Becker Muscular Dystrophy – Pipeline by Edgewise Therapeutics Inc, 2022

Becker Muscular Dystrophy – Pipeline by Epirium Bio Inc, 2022

Becker Muscular Dystrophy – Pipeline by Italfarmaco SpA, 2022

Becker Muscular Dystrophy – Pipeline by Milo Biotechnology LLC, 2022

Becker Muscular Dystrophy – Pipeline by PhaseBio Pharmaceuticals Inc, 2022

Becker Muscular Dystrophy – Pipeline by Santhera Pharmaceuticals Holding AG, 2022

Becker Muscular Dystrophy – Pipeline by Sarcomed AB, 2022

Becker Muscular Dystrophy – Pipeline by Scholar Rock Inc, 2022

Becker Muscular Dystrophy – Pipeline by Stealth BioTherapeutics Corp, 2022

Becker Muscular Dystrophy – Pipeline by Tivorsan Pharmaceuticals Inc, 2022

Becker Muscular Dystrophy – Dormant Projects, 2022

Becker Muscular Dystrophy – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Becker Muscular Dystrophy, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Becker Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Becker Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Becker Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.